A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [Lu]Lu-DOTATATE to favor its use in clinical practice.

Unlabelled: The role of internal dosimetry is usually proposed for investigational purposes in patients treated by RLT, even if its application is not yet the standard method in clinical practice. This limited use is partially justified by several concomitant factors that make calculations a complex process. Therefore, simplified dosimetry protocols are required.

Analysis of Pros and Cons in Using [Ga]Ga-PSMA-11 and [F]PSMA-1007: Production, Costs, and PET/CT Applications in Patients with Prostate Cancer.

The aim of this work is to compare [Ga]Ga-PSMA-11 and [F]PSMA-1007 PET/CT as imaging agents in patients with prostate cancer (PCa). Comparisons were made by evaluating times and costs of the radiolabeling process, imaging features including pharmacokinetics, and impact on patient management. The analysis of advantages and drawbacks of both radioligands might help to make a better choice based on firm data.

On site production of [F]PSMA-1007 using different [F]fluoride activities: practical, technical and economical impact.

Background: Prostate-specific membrane antigen is overexpressed in prostate cancer and it is considered a good target for positron emission tomography/computed tomography imaging of primary cancer and recurrent/metastatic disease, as well as for radioligand therapy. Different PSMA-analogues labeled with [Ga]gallium have been investigated, showing excellent imaging properties; however, only small amounts can be produced for each radiolabeling. Recently, a [F]fluoride labeled PSMA-inhibitor, [F]PSMA-1007, has been introduced, and it has ensured large-scale productions, overcoming this limitation of [Ga]PSMAs.